Top-Searched Lab Tests
Explore Conditions
Explore Biomarkers
Explore Diagnostic Labs
New Lab Tests
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| Cancerguard® Multi-Cancer Early Detection Test | Composite | Whole Blood | 14-null d | Exact Sciences |
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Signatera™ – Residual Disease Test (MRD) | NGS | Whole Blood, Tumor Tissue, Plasma | 7-10 d | Natera |
| MI Cancer Seek® | NGS | Tumor Tissue, Tissue, Plasma | 14 d | Caris Life Sciences |
| FoundationOne®CDx | NGS | Tissue | 8 d | Foundation Medicine |
Cancerguard® Multi-Cancer Early Detection Test
Methodology:Composite
Specimen:Whole Blood
TAT:14-null d
Lab:Exact Sciences
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Signatera™ – Residual Disease Test (MRD)
Methodology:NGS
Specimen:Whole Blood, Tumor Tissue, Plasma
TAT:7-10 d
Lab:Natera
MI Cancer Seek®
Methodology:NGS
Specimen:Tumor Tissue, Tissue, Plasma
TAT:14 d
Lab:Caris Life Sciences
FoundationOne®CDx
Methodology:NGS
Specimen:Tissue
TAT:8 d
Lab:Foundation Medicine
Featured Companion Diagnostics
| Test Name | Methodology | Specimen | TAT | Lab |
|---|---|---|---|---|
| xT CDx | NGS | Tissue, Whole Blood, Saliva | 10-14 d | Tempus AI |
| Vysis Chronic Lymphocytic Leukemia (CLL) Panel | Chromosomal / Cytogenetics | Whole Blood, Bone Marrow | 5 d | MPLN |
| PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) | Chromosomal / Cytogenetics | Tumor Tissue | — | ARUP Laboratories |
| nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay) | Other | Serum | 7-10 d | Labcorp |
| MyChoice® CDx Myriad HRD Companion Diagnostic Test | NGS | Tissue | 14 d | Myriad Genetics |
xT CDx
Methodology:NGS
Specimen:Tissue, Whole Blood, Saliva
TAT:10-14 d
Lab:Tempus AI
Vysis Chronic Lymphocytic Leukemia (CLL) Panel
Methodology:Chromosomal / Cytogenetics
Specimen:Whole Blood, Bone Marrow
TAT:5 d
Lab:MPLN
PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Methodology:Chromosomal / Cytogenetics
Specimen:Tumor Tissue
TAT:—
Lab:ARUP Laboratories
nAbCyte™ Anti‑AAVRh74var HB‑FE Assay (nAbCyte Assay)
Methodology:Other
Specimen:Serum
TAT:7-10 d
Lab:Labcorp
MyChoice® CDx Myriad HRD Companion Diagnostic Test
Methodology:NGS
Specimen:Tissue
TAT:14 d
Lab:Myriad Genetics
Featured Sponsored Testing
| Program Name | Therapeutic Area(s) | Condition | Lab |
|---|---|---|---|
| Renasight™ Genetic Kidney Panel | Nephrology | Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD) | Natera |
| FCSNext | Endocrinology | Familial Chylomicronemia Syndrome (FCS) | Ambry Genetics |
| NovoDETECT Primary Hyperoxaluria Panel | Nephrology | Primary Hyperoxaluria (PH) | Blueprint Genetics |
| Friedreich Ataxia Genetic Evaluation | Cardiology, Neurology | Friedrich Ataxia (FA) | Prevention Genetics |
| Early Stage Type 1 Diabetes Initial Screen | Endocrinology | Type 1 Diabetes | Revvity Omics, Inc. |
Renasight™ Genetic Kidney Panel
Therapeutic Area(s):Nephrology
Condition:Chronic Kidney Disease (CKD), APOL1-Mediated Kidney Disease (AMKD)
Lab:Natera
FCSNext
Therapeutic Area(s):Endocrinology
Condition:Familial Chylomicronemia Syndrome (FCS)
Lab:Ambry Genetics
NovoDETECT Primary Hyperoxaluria Panel
Therapeutic Area(s):Nephrology
Condition:Primary Hyperoxaluria (PH)
Lab:Blueprint Genetics
Friedreich Ataxia Genetic Evaluation
Therapeutic Area(s):Cardiology, Neurology
Condition:Friedrich Ataxia (FA)
Lab:Prevention Genetics
Early Stage Type 1 Diabetes Initial Screen
Therapeutic Area(s):Endocrinology
Condition:Type 1 Diabetes
Lab:Revvity Omics, Inc.